Shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) have been given a consensus recommendation of “Buy” by the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $19.71.
Several analysts have recently issued reports on the stock. Svb Leerink reiterated an “outperform” rating on shares of CymaBay Therapeutics in a research report on Thursday, February 21st. Zacks Investment Research upgraded shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of CymaBay Therapeutics in a research report on Friday, November 23rd. ValuEngine lowered shares of CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 24th. Finally, Leerink Swann assumed coverage on shares of CymaBay Therapeutics in a research report on Friday, February 22nd. They issued an “outperform” rating and a $22.00 target price on the stock.
Get CymaBay Therapeutics alerts:In other news, Director Carl Goldfischer sold 11,675 shares of the firm’s stock in a transaction dated Thursday, February 7th. The shares were sold at an average price of $9.02, for a total value of $105,308.50. Following the transaction, the director now directly owns 2,335 shares of the company’s stock, valued at $21,061.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Sujal Shah purchased 10,000 shares of the firm’s stock in a transaction dated Friday, December 21st. The stock was acquired at an average cost of $6.54 per share, for a total transaction of $65,400.00. Following the completion of the purchase, the chief executive officer now owns 110,000 shares of the company’s stock, valued at approximately $719,400. The disclosure for this purchase can be found here. Company insiders own 4.50% of the company’s stock.
Large investors have recently bought and sold shares of the company. Pearl River Capital LLC purchased a new position in shares of CymaBay Therapeutics in the fourth quarter worth about $74,000. D. E. Shaw & Co. Inc. purchased a new position in CymaBay Therapeutics during the fourth quarter worth about $82,000. PNC Financial Services Group Inc. raised its stake in CymaBay Therapeutics by 23.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 13,120 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 2,460 shares during the period. Virtu Financial LLC purchased a new position in CymaBay Therapeutics during the third quarter worth about $219,000. Finally, Metropolitan Life Insurance Co. NY raised its stake in CymaBay Therapeutics by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 19,900 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 15,542 shares during the period. 96.59% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ CBAY opened at $12.75 on Tuesday. CymaBay Therapeutics has a 52-week low of $6.31 and a 52-week high of $15.21. The stock has a market capitalization of $734.67 million, a PE ratio of -10.12 and a beta of 1.72.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
See Also: What is a Futures Contract?
No comments:
Post a Comment